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ABSTRACT Coronaviruses (CoVs) encode a mixture of highly conserved and novel
genes, as well as genetic elements necessary for infection and pathogenesis, raising
the possibility of common targets for attenuation and therapeutic design. In this
study, we focused on highly conserved nonstructural protein 16 (NSP16), a viral 2=O-
methyltransferase (2=O-MTase) that encodes critical functions in immune modulation
and infection. Using reverse genetics, we disrupted a key motif in the conserved
KDKE motif of Middle East respiratory syndrome CoV (MERS-CoV) NSP16 (D130A) and
evaluated the effect on viral infection and pathogenesis. While the absence of 2=O-
MTase activity had only a marginal impact on propagation and replication in Vero
cells, dNSP16 mutant MERS-CoV demonstrated significant attenuation relative to the
control both in primary human airway cell cultures and in vivo. Further examination
indicated that dNSP16 mutant MERS-CoV had a type I interferon (IFN)-based attenu-
ation and was partially restored in the absence of molecules of IFN-induced proteins
with tetratricopeptide repeats. Importantly, the robust attenuation permitted the use
of dNSP16 mutant MERS-CoV as a live attenuated vaccine platform protecting from
a challenge with a mouse-adapted MERS-CoV strain. These studies demonstrate the
importance of the conserved 2=O-MTase activity for CoV pathogenesis and highlight
NSP16 as a conserved universal target for rapid live attenuated vaccine design in an
expanding CoV outbreak setting.
IMPORTANCE Coronavirus (CoV) emergence in both humans and livestock repre-
sents a significant threat to global public health, as evidenced by the sudden emer-
gence of severe acute respiratory syndrome CoV (SARS-CoV), MERS-CoV, porcine epi-
demic diarrhea virus, and swine delta CoV in the 21st century. These studies
describe an approach that effectively targets the highly conserved 2=O-MTase activ-
ity of CoVs for attenuation. With clear understanding of the IFN/IFIT (IFN-induced
proteins with tetratricopeptide repeats)-based mechanism, NSP16 mutants provide a
suitable target for a live attenuated vaccine platform, as well as therapeutic develop-
ment for both current and future emergent CoV strains. Importantly, other ap-
proaches targeting other conserved pan-CoV functions have not yet proven effective
against MERS-CoV, illustrating the broad applicability of targeting viral 2=O-MTase
function across CoVs.
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The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012represents the second severe CoV to strike the human population since the
beginning of the 21st century (1). Similar to its predecessor, severe acute respiratory
syndrome CoV (SARS-CoV), MERS-CoV is characterized by severe lung infection and
high mortality rates (2). Associated with elderly patients and nosocomial spread,
MERS-CoV is likely harbored in camel populations with periodic reintroductions into
humans, followed by periodic nosocomial outbreaks in hospital settings (3). Impor-
tantly, with the continued rate of globalization, MERS-CoV remains an ongoing threat
for future outbreaks both in and outside the Middle East, as evidenced by the large
outbreak in South Korea (4). Together, these factors highlight the importance of
examining CoV pathogenesis and developing conserved therapeutic targets for the
treatment of current and future emergent strains.
Like all members of the CoV family, MERS-CoV maintains a balance of conserved and
novel viral proteins within its genome (5). It is a member of the group 2C CoV family,
and a wealth of distinct accessory open reading frames and nonstructural proteins
(NSPs) have already been established to have important roles in modulation of the host
immune response (6). Similarly, a number of viral proteins highly conserved in structure,
replication, and fidelity are also maintained in the CoV backbone (7). Among these,
MERS-CoV NSP16 provides a potent target for therapeutic development. A 2=O-
methyltransferase (2=O-MTase), CoV NSP16 has been implicated in the capping of viral
RNA and prevention of its recognition by the intracellular sensor MDA5 and antiviral
effectors, including members of the IFIT (interferon [IFN]-induced proteins with tetratri-
copeptide repeats) family (8). Generation of mutants with changes in the NSP16 KDKE
active site resulted in IFN-mediated in vitro and in vivo attenuation of both mouse
hepatitis virus (MHV) and SARS-CoV (9, 10). Therefore, an approach targeting MERS-CoV
NSP16 might be anticipated to result in attenuation and potentially provide a universal
platform for CoV vaccines against future emergent strains.
Using reverse genetics to target residues in the highly conserved active site, we
evaluated MERS-CoV infection outcomes in the context of inactive NSP16 (dNSP16).
Consistent with previous studies of SARS-CoV (10), the dNSP16 MERS-CoV mutant
maintained no significant attenuation in terms of replication or the initial host immune
response. However, both primary human airway epithelial (HAE) cells and in vivo studies
in a MERS-CoV mouse model demonstrated robust attenuation of dNSP16 mutant
growth and pathogenesis. Notably, attenuation was both IFN and IFIT1 dependent,
providing a clear mechanism for attenuation. Importantly, the dNSP16 mutant also
provided robust protection against a lethal MERS-CoV challenge and maintained
attenuation in the mouse-adapted backbone. Together, the results illustrate the broad
conservation and necessity of NSP16 in CoV pathogenesis and highlight the targeting
of this protein as a rapid-response platform for future emergent CoV strains.
RESULTS
A combination of structural and biochemical approaches has established a critical
role for CoV NSP16 in 2=O-MTase activity (Fig. 1A). Stabilized by interactions with NSP10
(orange), NSP16 has been identified as a structurally conserved AdoMet-dependent
methyltransferase (11); despite divergence in protein sequence across organisms, an
invariant KDKE motif (red) within the methyltransferase core is required to mediate its
activity (12). This KDKE motif is highly conserved within all of the NSP16 sequences
examined in the CoV family (Fig. 1B). Importantly, mutation of any of the KDKE residues
has been shown to ablate 2=O-MTase activity (11). In addition, previous alteration of this
motif in both group 2b SARS-CoV (10) and group 2a MHV (9) disrupted 2=O-MTase
activity and attenuated various aspects of infection. On the basis of high conservation
in the CoV family, we hypothesized that disruption of the KDKE motif would also
attenuate other emerging CoV families, including group 2c MERS-CoV. Utilizing a
MERS-CoV reversed genetic system (13), we disrupted the KDKE motif by mutating two
nucleotides to produce a D130A change (Fig. 1A). The resulting disrupted-NSP16
(dNSP16) mutant had no significant defect noted in stock titer generation (not shown);
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similarly, infection of both Vero cells and Calu-3 2B4 cells, a respiratory epithelial cell
line, at a low multiplicity of infection (MOI) demonstrated only modest attenuation at
late time points (Fig. 1C and D). Together, these results indicate that NSP16 activity is
not required for replication.
Similar in vitro host responses of SARS-CoV and MERS-CoV dNSP16 mutants.
Having established replication competence in both Vero and Calu-3 2B4 cells, we next
evaluated the induction of host pathways following infection. Calu-3 2B4 cells infected
at an MOI of 5 demonstrated no differences in replication (not shown) and only modest
differences in host induction (zero genes with a log2 change in expression of1.5-fold),
similar to observations with NSP16 mutant SARS-CoV compared with wild-type (WT)
SARS-CoV (10). However, unlike in studies with SARS-CoV, a rapid cytopathic effect
(CPE) by 24 h limited the analysis to early time points with WT and dNSP16 mutant
FIG 1 NSP16 is highly conserved in the CoV family. (A) MERS-CoV NSP16-NSP10 complex. Shown is NSP16 (gray) highlighting
the conserved KDKE motif (red) required for 2=O-MTase activity. Also shown is the NSP10 scaffold required for MERS-CoV
(orange). The inset displays conserved KDKE (left) and the D130A mutation (right) that disrupts function. Homology models
were created with Modeler in the Max-Planck Institute Bioinformatics Toolkit. The known crystal structure of the NSP16-NSP10
complex (3R24 in the RCSB Protein Data Bank) was used as the template structure (38). Homology models were then
manipulated with MacPyMol. (B) Heat maps were constructed from a set of representative CoVs from all four genogroups by
using alignment data paired with neighbor-joining phylogenetic trees built in Geneious (v.9.1.5) and visualized in EvolView
(http://evolgenius.info/). Trees show the degree of genetic similarity of NSP16 across CoV families. (C and D) Viral replication
of dNSP16 mutant MERS-CoV (red) relative to WT MERS-CoV (black) in Vero (C) and Calu-3 2B4 (D) cells following infection at
an MOI of 0.01. ***, P  0.001 (Student t test).
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MERS-CoV. Further David-based analysis compared the network host responses to
the MERS-CoV and SARS-CoV dNSP16 mutants (Fig. 2). Over the first 24 h of infection,
both MERS-CoV and SARS-CoV dNSP16 mutant infections showed no significant func-
tional enrichment of any categories relative to corresponding WT infections, consistent
with the lack of replication attenuation. However, at late times (24 h postinfection),
SARS-CoV produced robust changes in several host pathways, including cytokine
responses, inflammation, and extracellular activity. Similarly, changes in apoptosis,
transcription repression, and regulation of phosphorylation indicated a host response
more hostile to viral infection. While a more rapid CPE following both WT and dNSP16
mutant MERS-CoV infections precluded an equivalent finding at late time points, the
SARS-CoV results suggest that the absence of NSP16 activity eventually initiates host
response changes that contribute to attenuation at late time points.
MERS-CoV dNSP16 mutant attenuated in primary and in vivomodels. To further
examine the replicative capacity of the dNSP16 mutant, we infected both HAE cells
and mice expressing human dipeptidyl peptidase 4, the receptor for MERS-CoV. Primary
HAE cell cultures were challenged with WT and dNSP16 MERS-CoV at a low MOI
(Fig. 3A). While robust replication was observed following WT infection, dNSP16
MERS-CoV had significant attenuation that corresponded well to previous results
obtained with dNSP16 mutant SARS-CoV (10). We next examined dNSP16 mutant
MERS-CoV replication phenotypes in the context of in vivo infection by using an
adenovirus BALB/c mouse transduction model (14). While neither infection produced
weight loss (not shown), WT MERS-CoV replicated efficiently at both days 2 and 4
postinfection (Fig. 3B); in contrast, no detectable replication was seen following infec-
tion with dNSP16 mutant MERS-CoV. The lack of replication may be due to residual IFN
FIG 2 dNSP16 mutant MERS-CoV infection produces minimal changes in early host responses. Changes in functional host gene clusters on the basis of RNA
expression following infection at an MOI of 5 of Calu-3 2B4 cells with dNSP16 mutant MERS-CoV (left) or SARS-CoV (right) relative to the WT control virus. The
heat map plots significant enrichment of clustered functional categories (as determined by David analysis) for each mutant over time. Only marginal changes
were noted during the first 24 h for both SARS-CoV and MERS-CoV dNSP16 mutants. After 24 h (right), significant changes due to SARS-CoV were noted;
MERS-CoV had a significant CPE after 24 h postinfection, precluding analysis.
Menachery et al.
November/December 2017 Volume 2 Issue 6 e00346-17 msphere.asm.org 4
responses associated with initial adenovirus infection. For greater clarity, we next
infected CRISPR-Cas9-targeted mice that include mutations in Dpp4 at positions 288
and 330 (288-330/) conferring efficient WT MERS-CoV infection and growth in mice
but no clinical disease (15). Following infection, no changes were observed in weight
loss in either group of mice, consistent with previous findings (data not shown).
However, absence of NSP16 activity severely attenuated dNSP16 mutant virus replica-
tion at both days 2 and 4 postinfection (Fig. 3C). Coupled with data from HAE cell
cultures and the adenovirus model, the results demonstrate clear attenuation of
dNSP16 mutant MERS-CoV relative to the control.
dNSP16 mutant MERS-CoV attenuation is mediated by IFN and IFIT1. Having
established a deficit in dNSP16 mutant MERS-CoV replication in relevant in vitro and in
vivo models, we next sought to evaluate the mechanism of attenuation. Previous work
by our lab and others had established increased susceptibility of dNSP16 mutants to
type I IFN (9, 10); however, dNSP16 mutant SARS-CoV had not shown augmented type
I IFN stimulation following infection (10). Consistent with this finding, infection with
dNSP16 mutant MERS-CoV produced stimulation of type I IFN transcript similar to that
seen following in vivo infection of Dpp4 mutant (288-330/) CRISPR mice with the WT
virus (Fig. 4A). In contrast, while both the WT and mutant viruses were sensitive to IFN
treatment, dNSP16 mutant MERS-CoV had a significant reduction in replication relative
to the control virus (Fig. 4B). These attenuation results are consistent with reports of
NSP16 mutants of other CoVs and are in contrast to the equivalent replication observed
without pretreatment (Fig. 1C) (8). Extending this analysis further, we examined the role
of IFIT1 and IFIT2 gene expression in this attenuation phenotype in previously con-
FIG 3 dNSP16 mutant MERS-CoV is attenuated in primary cultures and in vivo. (A) Primary HAE cells
infected with WT (black) or dNSP16 mutant (red) MERS-CoV at an MOI of 0.01 and monitored over a time
course. (B) Day 2 and 4 lung titers of adenovirus-transduced mice expressing human Dpp4 infected with
WT (black) or dNSP16 mutant (red) MERS-CoV. (C) Day 2 and 4 lung titers of 288-330/ CRISPR-Cas9-
targeted mice infected with WT (black) or dNSP16 mutant (red) MERS-CoV. *, P  0.05; **, P  0.01; ***,
P  0.001. (Student t test). n  4 for each experimental group at each time point over multiple
experiments.
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structed stable short hairpin RNA (shRNA) knockdown cell lines (10). Similar to SARS-
CoV, knockdown of IFIT1 augmented replication of dNSP16 mutant MERS-CoV in the
context of type I IFN pretreatment (Fig. 4C). In addition, knockdown augmented WT
MERS-CoV infection, suggesting sensitivity to IFIT1 activity despite the presence of
NSP16. Notably, IFIT2 knockdown had only a modest, nonsignificant impact on repli-
cation, contrasting with results obtained with SARS-CoV. Overall, the data indicate that
dNSP16 mutant MERS-CoV attenuation is driven by sensitivity to type I IFN mediated by
the activity of IFIT1 rather than augmented IFN responses.
NSP16 mutant vaccination protects from a lethal MERS-CoV challenge. On the
basis of IFN and IFIT1 attenuation phenotypes, targeting of NSP16 offers a potential
platform strategy for live attenuated vaccine generation. While previous work by our
group had shown that the dNSP16 mutant SARS-CoV conferred protection from a lethal
challenge, similar phenotypes in other more distant CoVs are essential for establishing
universal principles of attenuation across a virus family. To test this hypothesis, Dpp4
288-330/ mutant mice were vaccinated with dNSP16 mutant MERS-CoV and subse-
quently challenged with a mouse-adapted MERS-CoV strain (Fig. 5) (15). Following the
challenge, dNSP16 mutant-vaccinated mice showed only modest weight loss, in sig-
nificant contrast to the severe disease seen in the control group (Fig. 5A). In addition,
both viral replication and lung hemorrhage were significantly reduced in the context of
the dNSP16 mutant vaccine (Fig. 5B and C). Importantly, serum analysis revealed robust
virus neutralization with values similar to those seen in serum from WT virus-infected
mice (Fig. 5D). Together, the results indicate that dNSP16 mutant MERS-CoV can
function as a vaccine platform that not only induces high levels of neutralizing
antibodies but provides compete protection from a lethal MERS-CoV challenge.
NSP16 mutation attenuates mouse-adapted MERS-CoV. Despite conferring pro-
tection in the WT MERS-CoV backbone, it was unclear if the NSP16 mutant would be
sufficiently attenuated in a virulent MERS-CoV backbone. To address this question, we
inserted the dNSP16 mutation (D130A) into the mouse-adapted MERS-CoV backbone
(15). Following infection, mouse-adapted MERS-CoV produced rapid weight loss and
death (Fig. 6A). In contrast, the mouse-adapted dNSP16 mutant produced only modest
weight loss and 100% survival following infection. In addition, the replication of the
dNSP16 mutant was significantly attenuated relative to that of the WT at days 2 and 4
postinfection (Fig. 6B). Finally, hemorrhage scoring of the lung revealed minimal
disease in dNSP16 mutant-immunized mice relative to control mice at day 4 postin-
fection (Fig. 6C). Overall, the results demonstrate robust attenuation of MERS-CoV
pathogenesis in the context an NSP16 mutation.
FIG 4 dNSP16 mutant MERS-CoV attenuated by type I IFN treatment via IFIT1. (A) IFN-, IFN-4, and IFN-7 RNA expression in the lungs
of 288-330/ CRISPR-Cas9-targeted mice at 2 days postinfection with WT (black) or dNSP16 mutant (red) MERS-CoV. Values are
representative of log2 fold expression relative to mock-infected lungs as measured by real-time reverse transcription-PCR. (B) Vero cells
were treated with type I IFN (1,000 U) 16 h prior to infection with either WT (black) or dNSP16 mutant (red) MERS-CoV. (C) Vero cells
expressing shRNA targeting IFIT1 (blue) or IFIT2 (green) or a no-shRNA control cells (black) were pretreated with IFN- (PBL Laboratories)
and infected with WT (left) or dNSP16 mutant (right) MERS-CoV. *, P  0.05; **, P  0.01; ***, P  0.001 (Student t test).
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DISCUSSION
In the context of the ongoing MERS-CoV outbreak, the development of universal
platform strategies to attenuate emerging and contemporary CoVs is a significant
priority. In this study, we demonstrate the critical importance of NSP16 function to
MERS-CoV pathogenesis in vitro and in vivo. Similar to MHV and SARS-CoV (9, 10), the
disruption of 2=O-MTase activity in MERS-CoV had no significant impact on replication
or early host response patterns in vitro. However, dNSP16 mutant MERS-CoV demon-
strated attenuated replication and growth in primary HAE cell cultures, as well as
FIG 5 dNSP16 mutant MERS-CoV protects from a lethal challenge. Graphs show weight losses (A), day
4 viral titers (B), and hemorrhage scores (C) following a challenge of 288-330/ CRISPR-Cas9-targeted
mice vaccinated with dNSP16 mutant MERS-CoV (red) or mock vaccinated (black) with 106 PFU of
passaged mouse-adapted MERS-CoV (15). (D) Plaque reduction neutralization with serum fromWT (black)
or dNSP16 mutant (red) MERS-CoV-vaccinated mice. *, P  0.05; **, P  0.01; ***, P  0.001 (Student
t test). n  4 for each experimental group at each time point in multiple experiments.
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reduced disease in vivo, relative to the WT virus. Further examination revealed in-
creased sensitivity to type I IFN in an IFIT-dependent manner. Notably, this IFN/IFIT-
based attenuation phenotype provided robust protection from a lethal challenge
following vaccination with the dNSP16 mutant. Importantly, the NSP16 mutant also was
fully attenuated in a highly virulent mouse-adapted MERS-CoV backbone. These results,
coupled with previous work with other CoVs, highlight the viral 2=O-MTase activity as
a potential universal platform for therapeutic treatment and vaccine development for
current and future emergent human and animal CoVs.
Similar to previously viral methyltransferase mutants of both flaviviruses and CoVs,
substitution with the highly conserved KDKE motif alters the pathogenicity of MERS-
CoV. Like SARS-CoV mutants (10), dNSP16 mutant MERS-CoV had normal replication
but was attenuated in the context of type I IFN and IFIT activity. Notably, the absence
of 2=O-MTase activity did not result in an increased type I IFN response, suggesting that
loss of NSP16 produces a sensitivity to IFIT activity not seen in the WT virus. While the
mutant RNA should induce greater IFN activation through MDA5, multiple other CoV
proteins have been shown to disrupt immune recognition (16). Similarly, viral processes
including replication within double membrane vesicles may also limit IFN stimulation.
Together, the results indicate that even without NSP16, CoVs are able to control IFN
stimulation and replicate as efficiently as the WT virus. However, NSP16 is needed to
protect the viruses once the IFN-stimulated gene (ISG) effector response is initiated.
The attenuation of the MERS-CoV NSP16 mutant also provides evidence supporting
the targeting of viral 2=O-MTase as a global therapeutic strategy against emergent RNA
viruses. Previous work with both flaviviruses and CoVs has demonstrated robust
attenuation by targeting the conserved KDKE motif of the viral 2=O-MTase (8, 17, 18).
FIG 6 dNSP16 mutation attenuates the virulence of a mouse-adapted MERS-CoV strain. Graphs show
weight losses (A), day 4 viral titers (B), and hemorrhage scores (C) following infection of 288-330/
CRISPR-Cas9-targeted mice infected with 106 PFU of MERS-CoV MA1 (black) or dNSP16 MA1 (red) at days
2 and 4. *, P 0.05; **, P 0.01; ***, P 0.001 (Student t test). n3 for each group at each time point
in two experiments.
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Importantly, 2=O-MTase activity is the only known function for NSP16 and it appears
completely dispensable for CoV replication in the absence of a strong IFN response (8).
In contrast, flaviviruses without nsp5-encoded methyltransferase activity are much
more sensitive to innate immune responses (19); mutants of West Nile virus, dengue
virus, and Japanese encephalitis virus are highly replication attenuated at early time
points (20, 21). While diminished virus yields likely reduce flavivirus vaccine utility in
vivo, robust propagation of both MERS-CoV and SARS-CoV dNSP16 mutants provides a
useful parameter for vaccine generation. For both viral families, drugs targeting 2=O-
MTase activity may have great efficacy if paired with stimulation of the IFN-responsive
genes, including that for IFIT1 (8, 17). Overall, the results indicate that viral 2=O-MTase
activity is a critical determinant of pathogenesis and can be leveraged to develop
therapeutic treatments.
NSP16 also represents the third highly conserved CoV protein targeted as the basis
of a vaccine platform. Previous work by our group demonstrated the importance of CoV
fidelity for infection and pathogenesis (22); disruption of the exonuclease activity of
NSP14 rendered attenuated, reversion-proof versions of both MHV and SARS-CoV
(22–24). For SARS-CoV, the disruption served as the basis of a successful live attenuated
vaccine (22). Similarly, groups have targeted the envelope protein of SARS-CoV and
defined a key inflammatory role for E protein in pathogenesis. SARS mutants targeting
E function also conferred protection from a lethal challenge (25, 26). For both NSP14
and E mutants, fidelity and inflammation induction are partially responsible for atten-
uation. However, both viral mutants also maintain replication attenuated in terms of
kinetics and yields, potentially complicating their use as vaccine platforms, especially in
outbred populations (22, 26). Importantly, the NSP14 mutant has not yet been recov-
ered within the context of MERS-CoV and failure has been reported in group I CoVs (27).
Similarly, disruption of the E protein renders MERS-CoV, transmissible gastroenteritis
virus, and MHV replication deficient without exogenous complementation (28–30); this
broad attenuation of the delta E mutant potentially limits its use as a live attenuated
vaccine. In contrast, dNSP16 mutant MERS-CoV maintains robust propagation, as well
as IFN/IFIT-based attenuation phenotypes. Together, these results suggest that target-
ing ofNSP16 may be the most broadly applicable platform for CoV attenuation.
Despite the success of NSP16 mutants in protection studies with SARS-CoV and
MERS-CoV, several additional parameters must be considered in the context of CoV
vaccination. Previous work by our group has demonstrated failures of CoV subunit
vaccines in aged animals and in the context of a heterologous challenge (31). With the
aged representing a population with high mortality rates and marginal vaccination
success, the efficacy of the NSP16 mutant in this population is paramount in its pursuit
as a platform. Similarly, the existence of numerous CoVs in animal populations raises
concerns about heterologous challenges from emergent viruses (32, 33). Prior reports
had also demonstrated vaccine-induced disease following heterologous challenges
with related SARS-like viruses (31, 34). With this in mind, NSP16-vaccinated mice will
need to be examined in the context of a heterologous challenge to determine if
vaccine-induced pathology occurs. Together, these two factors represent important
checkpoints in the pursuit of NSP16 as a universal CoV vaccine platform.
In addition to aging and heterologous challenges, reversion and baseline patho-
genesis also represent important risks that must be evaluated in the context of an
NSP16 vaccine. While the NSP14 SARS vaccine was absent sterilizing immunity in
immunodeficient mice, the lack of reversion over time in vivo indicates safety in the
approach (22). In contrast, passage of the E mutant rendered a novel mutant that
transplanted a critical ion channel function from another viral protein and thus restored
partial virulence (35). Studies examining the reversion potential of NSP16 are critical
prior to its use as a vaccine; these concerns are especially important considering that
both the SARS-CoV and MERS-CoV dNSP16 mutants have robust replication, permitting
additional opportunities for reversion (10). In addition, equivalent host immune re-
sponses during early infection may produce substantial damage prior to IFN/IFIT-based
attenuations, most notably in aged and immunocompromised mice. Therefore, despite
MERS-CoV NSP16 Is Necessary for Pathogenesis
November/December 2017 Volume 2 Issue 6 e00346-17 msphere.asm.org 9
the promise of successful attenuation in multiple CoV backbones, several additional
metrics must be examined prior to the use of NSP16 mutants as a universal CoV vaccine
platform.
Overall, the present study demonstrates that targeting of 2=O-MTase activity is a
robust strategy to attenuate MERS-CoV and other emergent CoVs. In the absence of
NSP16 activity, the MERS-CoV mutant is sensitive to type I IFN in an IFIT-dependent
manner, providing a clear attenuation mechanism. Importantly, unlike other conserved
CoV platforms, the NSP16 mutant is both viable and robust enough to be used as an
effective live attenuated vaccine. While further vaccine characterization is required, the
results indicate that disruption of CoV NSP16 activity can be the basis of therapeutic
strategies for both current and future emergent CoV infections in both human and
animal populations.
MATERIALS AND METHODS
Cells and viruses. The WT, mutant, and mouse-adapted versions of MERS-CoV used in this study
were previously described (13, 15) and were cultured on Vero 81 cells grown in Dulbecco’s modified
Eagle’s medium or Opti-MEM (Gibco, Carlsbad, CA) and 5% fetal bovine serum (HyClone, South Logan,
UT) along with antibiotic/antimycotic (Gibco, Carlsbad, CA). Growth curves in Vero, Calu-3 2B4, and HAE
cells were performed as previously described, with examination of multiple samples (n 3) at each time
point (9, 31). Briefly, cells were washed with phosphate-buffered saline (PBS) and inoculated with virus
or mock diluted in PBS for 40 min at 37°C. Following inoculation, cells were washed three times and fresh
medium was added to signify time zero. Samples were harvested at the time points described. For IFN
pretreatments, 100 U/ml recombinant human IFN- (PBL Laboratories) was added to cells 16 h prior to
inoculation, and the cells were infected as described above. Stable shRNA knockdown Vero cell lines for
both IFIT1 and IFIT2 were previously described for previous CoV studies and had phenotypic validation
(10). All virus cultivation was performed in a biosafety level 3 laboratory with redundant fans in biosafety
cabinets as described previously by our group (32, 33). All personnel wore powdered air purifying
respirators (3M Breathe Easy) with Tyvek suits, aprons, and booties and were double gloved.
Construction of WT and NSP16 mutant viruses. Both WT and mutant viruses were derived from
either MERS-CoV EMC or a corresponding mouse-adapted (MA1) infectious clone as previously described
(13). For NSP16 mutant construction, the D130A mutation changed the sequence from the MERS-CoV E
fragment, which was cloned into the pSMART vector (Lucigen) and used for alanine scanning mutagen-
esis of conserved residues in nsp16. For the D130A change, a product was generated by PCR with primers
against MERS-CoV NSP16 [fragment 1, EMC:E#2() (TGAACTACCTGTAGCTGTAG) and EMC:EmuC()
(NNNNNNGCTCTTCTCGCGGAAATAACAAGATCCACTTG); fragment 2, EMC:EmuC() (NNNNNNGCTCTTC
CGCGATGTATGATCCTACTACTAAG) and EMC:E#6() (CAACCTCAATACAAGCAGAC)]. The two resulting
products were digested with SapI (in boldface) and ligated overnight with T4 DNA ligase. This product
was then digested with PpuMI and NsiI and used to replace the region of the EMC E plasmid (puc57) that
had been similarly digested. Thereafter, plasmids containing WT and mutant MERS-CoV genome frag-
ments were amplified, excised, ligated, and purified. In vitro transcription reactions were then performed
to synthesize full-length genomic RNA, which was transfected into Vero E6 cells. The medium from
transfected cells was harvested and used as seed stock for subsequent experiments. Viral mutants were
confirmed by sequence analysis prior to use. Synthetic construction of NSP16 mutants was approved by
the University of North Carolina Institutional Biosafety Committee.
RNA isolation, microarray processing, and identification of DE. RNA isolation and microarray
processing, quality control, and normalization from Calu-3 2B4 cells were carried out as previously
described (36). Differential expression (DE) was determined by comparing virus-infected replicates with
time-matched mock-treated replicates. Criteria for DE in determining the consensus ISG list were an
absolute log2 change of 1.5-fold and a false-discovery rate-adjusted P value of 0.05 for a given time
point.
Clustering and functional enrichment. Genes identified as differentially expressed were used to
generate clustered expression heat maps. Hierarchical clustering (using Euclidean distance and complete
linkage clustering) was used to cluster gene expression according to behavior across experimental
conditions. The David online resource (https://david.ncifcrf.gov/) was used to acquire functional enrich-
ment results for the genes in each cluster. David output was manually summarized for each cluster. Plots
were generated with R.
Ethics statement. This study was carried out in accordance with the recommendations for the care
and use of laboratory animals of the Office of Laboratory Animal Welfare (OLAW), National Institutes of
Health. The Institutional Animal Care and Use Committee (IACUC) of the University of North Carolina at
Chapel Hill (UNC; permit A-3410-01) approved the animal study protocols used in this study (IACUC
protocols 15-009 and 13-072).
Mouse infections and vaccinations. Ten- to 20-week-old BALB/c (Envigo/Harlan) or CRISPR-Cas9-
targeted 288-330/ C57BL/6 mice were anesthetized with ketamine and xylazine (in accordance with
UNC IACUC guidelines) and intranasally inoculated with a 50-l volume containing 106 PFU of WT
MERS-CoV, dNSP16 mutant MERS-CoV, mouse-adapted variants, or PBS (mock inoculation) as indicated
in the figure legends. Infected animals were monitored for weight loss, morbidity, and clinical signs of
disease, and lung virus titers were determined as described previously (37). In vivo adenovirus transduc-
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tion with Dpp4 were performed as previously described (14). For vaccination experiments, 10- to
20-week-old 288-330/ mice were infected with 106 PFU of dNSP16 mutant MERS-CoV as described
above, monitored for clinical symptoms for 7 days, and then challenged 4 weeks postvaccination with
106 PFU of mouse-passaged MERS-CoV MA1. Animal housing, care, and experimental protocols were in
accordance with UNC IACUC guidelines.
Data availability. Raw microarray data for these studies were deposited in publicly available
databases at the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (37)
and are accessible through GEO series GSE65574.
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